度洛西汀治疗躯体化障碍和持续性躯体形式疼痛障碍对照研究

A control study of duloxetine in the treatment of somatization disorder vs .persistent somatoform pain disorder

目的：探讨度洛西汀治疗躯体化障碍和持续性躯体形式疼痛障碍患者的临床疗效。方法将33例躯体化障碍患者设为A组，37例持续性躯体形式疼痛障碍患者设为B组，两组均口服度洛西汀治疗，观察12周。于治疗前后采用汉密顿焦虑量表及视觉疼痛模拟量表评定临床疗效。结果治疗12周末A组有效率77．42％，B组为97．06％，A 组显著低于B组（χ2＝4．10，P＜0．05）。结论度洛西汀对躯体化障碍和持续性躯体形式疼痛障碍患者均有较好疗效，但对持续性躯体形式疼痛障碍患者的疗效更显著。

Objective To explore the efficacy of duloxetine in the treatment of so-matization disorder （SD） and persistent somatoform pain disorder （PSPD） .Meth-ods Thirty-three SD patients were assigned to group A and 37 PSPD ones to B , both groups took orally duloxetine for 12 weeks .Efficacies were assessed with the Hamilton Anxiety Scale （HAMA） and Visual Analogue Scale （VAS） before and after treatment .Results At the end of the 12th week effective rate was significantly lower in group A than in B （77 .42% vs .97 .06% ,χ2 = 4 .10 , P〈0 .05） .Conclusion Duloxetine has an evident effect in both SD and PSPD patients ,especially the latter .